PMID- 37111789
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230501
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 15
IP  - 4
DP  - 2023 Apr 21
TI  - A Multi-Criteria Decision Aid Tool for Radiopharmaceutical Selection in Tau PET 
      Imaging.
LID - 10.3390/pharmaceutics15041304 [doi]
LID - 1304
AB  - The accumulation of pathologically misfolded tau is a feature shared by a group 
      of neurodegenerative disorders collectively referred to as tauopathies. 
      Alzheimer's disease (AD) is the most prevalent of these tauopathies. 
      Immunohistochemical evaluation allows neuropathologists to visualize 
      paired-helical filaments (PHFs)-tau pathological lesions, but this is possible 
      only after death and only shows tau in the portion of brain sampled. Positron 
      emission tomography (PET) imaging allows both the quantitative and qualitative 
      analysis of pathology over the whole brain of a living subject. The ability to 
      detect and quantify tau pathology in vivo using PET can aid in the early 
      diagnosis of AD, provide a way to monitor disease progression, and determine the 
      effectiveness of therapeutic interventions aimed at reducing tau pathology. 
      Several tau-specific PET radiotracers are now available for research purposes, 
      and one is approved for clinical use. This study aims to analyze, compare, and 
      rank currently available tau PET radiotracers using the fuzzy preference ranking 
      organization method for enrichment of evaluations (PROMETHEE), which is a 
      multi-criteria decision-making (MCDM) tool. The evaluation is based on relatively 
      weighted criteria, such as specificity, target binding affinity, brain uptake, 
      brain penetration, and rates of adverse reactions. Based on the selected criteria 
      and assigned weights, this study shows that a second-generation tau tracer, 
      [(18)F]RO-948, may be the most favorable. This flexible method can be extended 
      and updated to include new tracers, additional criteria, and modified weights to 
      help researchers and clinicians select the optimal tau PET tracer for specific 
      purposes. Additional work is needed to confirm these results, including a 
      systematic approach to defining and weighting criteria and clinical validation of 
      tracers in different diseases and patient populations.
FAU - Ozsahin, Ilker
AU  - Ozsahin I
AUID- ORCID: 0000-0002-3141-6805
AD  - Brain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, 
      New York, NY 10065, USA.
AD  - Operational Research Center in Healthcare, Near East University, Nicosia 99138, 
      TRNC, Turkey.
FAU - Onakpojeruo, Efe Precious
AU  - Onakpojeruo EP
AUID- ORCID: 0000-0001-8582-409X
AD  - Operational Research Center in Healthcare, Near East University, Nicosia 99138, 
      TRNC, Turkey.
FAU - Uzun, Berna
AU  - Uzun B
AD  - Operational Research Center in Healthcare, Near East University, Nicosia 99138, 
      TRNC, Turkey.
AD  - Department of Statistics, Carlos III University of Madrid, Getafe, 28903 Madrid, 
      Spain.
FAU - Uzun Ozsahin, Dilber
AU  - Uzun Ozsahin D
AD  - Operational Research Center in Healthcare, Near East University, Nicosia 99138, 
      TRNC, Turkey.
AD  - Medical Diagnostic Imaging Department, College of Health Sciences & Research 
      Institute for Medical and Health Sciences, University of Sharjah, Sharjah P.O. 
      Box 26666, United Arab Emirates.
FAU - Butler, Tracy A
AU  - Butler TA
AD  - Brain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, 
      New York, NY 10065, USA.
LA  - eng
PT  - Journal Article
DEP - 20230421
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC10147085
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - decision analysis
OT  - fuzzy PROMETHEE
OT  - positron emission tomography
OT  - radiopharmaceuticals
OT  - tauopathies
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/28 06:42
MHDA- 2023/04/28 06:43
PMCR- 2023/04/21
CRDT- 2023/04/28 01:48
PHST- 2023/02/20 00:00 [received]
PHST- 2023/04/09 00:00 [revised]
PHST- 2023/04/19 00:00 [accepted]
PHST- 2023/04/28 06:43 [medline]
PHST- 2023/04/28 06:42 [pubmed]
PHST- 2023/04/28 01:48 [entrez]
PHST- 2023/04/21 00:00 [pmc-release]
AID - pharmaceutics15041304 [pii]
AID - pharmaceutics-15-01304 [pii]
AID - 10.3390/pharmaceutics15041304 [doi]
PST - epublish
SO  - Pharmaceutics. 2023 Apr 21;15(4):1304. doi: 10.3390/pharmaceutics15041304.